ADME & Predictive Toxicology and Discovery Congress Chemistry 2012

13-14 March 2012, Munich, Germany

Recordings of the following presentations are available to access:


ADME & Predictive Toxicology Conference

Towards Predicating the Genotoxic Potential of Aromatic Amines
Michael Kranz, Computational Chemist, GSK

When is a Genotoxin not a Genotoxin?
Richard Walmsley, Professor, University of Manchester and Gentronix Ltd

Biotransformation: Still a Bottleneck for in Vitro Kinetic and Dynamic Approaches
Sandra Coecke, Laboratory Leader, European Commission, Joint Research Center

In Silico Toxicology: Where are We at and Where are We Going?
John C. Dearden, Emeritus Professor of Medicinal Chemistry, Liverpool John Moores University

In Vitro, Ex Vivo and in Models to Develop New Therapies for Renal Diseases
Frederick W. K. Tam, Reader in Renal Medicine, Imperial College London

MetABOLITES and SAFETY, the MIST and ICH-M3 GUIDANCE and Their Impact on ADME
Gerhard Gross, Head of Drug Metabolism, Lundbeck Pharma

Rationalizing ADME in the Current Regulatory and Business Environment
Robert Guttendorf, Senior Consultant, Aclairo Pharmaceutical Development Group

Defence and Adaptation in Drug-Mediated Liver Toxicity
Christopher Goldring, Reader, MRC Centre for Drug Safety Science, University of Liverpool

Regulation of Cytochrome P450s and Nuclear Receptor by microRNAs and its Toxicological Implications
Tsuyoshi Yokoi, Reader, Professor, Drug Metabolism and Toxicology Laboratory, Kanazawa University

Discovery Chemistry Congress - Fragment Based Durg Discovery

Current Challenges in Fragment-Based Drug Discovery
Roderick E Hubbard, Professor, University of York

The Versatility of Fragment Screening Approaches and the Application of Fragment Binding Information in Drug
Stefan Geschwindner, Principal Scientist, AstraZeneca

Fragment-Based Screening and Structure-Based Design at ICR: Discovering High Quality Leads in Cancer Drug Discovery
Rob Van Montfort, Leader, Hit Discovery and Structural Design Unit, Institute of Cancer Research

Fragment-Based Drug Discovery - Getting in Shape
Doris Hafenbradl, Senior Director Biology & Natural Products, Biofocus

Fragment Based de novo Ligand Design: A Valuable Optimisation Tool in Fragment Based Lead Discovery
Peter Johnson, Research Professor, University of Leeds

Discovery Chemistry Congress - Chemistry Outsourcing

Outsourcing Chemical Synthesis in the Drug Discovery Process
Gunter Festel, Co-Founder, Autodisplay Biotech

Outsourcing in Discovery Chemistry: Strategy, Selection, Success
Hansjoerg Lehmann, Lab Head, Preparation Laboratories, PSB, Novartis Institutes for BioMedical Research

Protecting IP in Chemistry Outsourcing
Hiroshi Sheraton, Partner, McDermott Will & Emery

Emerging Outsourcing Destinations Pharmas Strategies and Growth Drivers
Jim Zhang, President, JZMed

An Open Innovation Ecosystem for Drug Discovery
Michael Barnes, Co-Founder, OI Pharma Partners Ltd

US Patent Law of 2011: The Good, the Bad, and The Expensive
Thomas Saunders, Of Counsel, Rissman Hendricks & Oliverio

If you require any further information please contact:

registrations@selectbio.com
+44 (0)1787 315110